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We  have  developed  two  methods  to  enhance  the  sensitivity  of  chemo-  and/or  radioresistant  oral  squa-
mous  carcinoma  cells  (OSCC).
One is a method  to  inhibit  a chemoresistant  gene  and  to enhance  sensitivity  to  chemotherapy.  Most  of
the  cases  with  resistance  to cis-diaminedichloro-platinum  II (cisplatin,  CDDP)  shows  signiﬁcant  upregu-
lated  expression  of phosphodiesterase  3B  (PDE3B)  and  inhibition  of  PDE3B  by  cilostazol,  which  is  clinically
used  as an antiplatelet  drug  for peripheral  vascular  disease,  suppressing  multidrug  resistance-associated
proteins  (MRPs),  a subfamily  of  adenosine  triphosphate  (ATP)-binding  cassette  (ABC)  transporters,  thus
resulting  in an  increased  amount  of anticancer  drugs  such  as  CDDP.  The  combination  usage  of cilostazol
and  CDDP  in vitro  and in  vivo  indicated  greater  growth  suppression  of  chemoresistant  OSCC  than  that  of
either  cilostazol  alone  or CDDP  alone.  The  other  method  involves  using  a drug  that  inhibits  radioresistance
and  enhances  sensitivity  to radiotherapy.  Human  oral  squamous  cancer  cell lines  exhibiting  radioresis-
tance  show  signiﬁcant  upregulated  expression  of  the  ﬁbroblast  growth  factor  receptor  3 (FGFR3).  In  vitro
and  in  vivo,  PD173074,  a chemical  agent  inhibiting  FGFR3,  showed  signiﬁcant  enhanced  effect  of radia-
tion  therapy  on  radioresistant  cancer  cells.  These  results  provided  novel  information  on which  to  base
further  mechanistic  study  on  developing  strategies  to improve  outcomes  with  concurrent  chemo-  and/or
radiotherapy.
©  2015  Japanese  Stomatological  Society.  Published  by Elsevier  Ltd.  All  rights  reserved.ontents
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Although the antitumor effect of cis-diaminedichloro-platinum
II  (cisplatin (CDDP)) has been proven in a board range of malig-
nant tumors, its usefulness is limited due to severe side effects and
acquired resistance [1–4]. Likewise, despite progress in radiation
techniques, a signiﬁcant proportion of patients who  undergo irra-
diation to treat cancer develop local–regional recurrence or new
primary cancers after completion of high-dose therapy. Patients
undergoing radiotherapy for oral malignancies also develop painful
eserved.
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ucositis, which often results in decreased oral intake, weight loss,
ecreased quality of life, and unforeseen treatment interruptions.
owever, chemo- and/or radiotherapy is important, especially for
atients with advanced disease. Conventional therapies includ-
ng chemo- and/or radiotherapy cannot frequently cure malignant
umors, and new treatments are clearly required.
The recent progress of the microarray technique has revealed
he role of reliable markers of CDDP resistance in various human
umors, including squamous cell carcinomas (SCCs) of the lung,
ervix, esophagus, and the head and neck [5–8] and associated
umor gene(s) expression with the CDDP response that serves as
rognostic indicators of survival in lung cancer, ovarian cancer,
ral cancer, osteosarcoma, and malignant melanoma [9–13]. Recent
icroarray analysis combined with the pathway analysis has also
dentiﬁed gene indicators, including biomarkers for genetic alter-
tions, which are needed to predict the outcome of radiotherapy
or individual patients more accurately and to provide a novel ther-
py that inhibits/accelerates these genes. However, there have been
ery few clinical applications as anticancer drugs. We  have stud-
ed new advanced anticancer technologies including gene therapy,
eavy ion radiation, and immune therapy as we have been the lead-
ng laboratory of the 21st Century Center of Excellence Program,
hich is one of the national programs in Japan. Although these new
ethods are very important, they are very expensive and inconve-
ient. We believe that a cheap and convenient method will be more
ffective for large number of patients with cancer.
We  have developed several methods to inhibit resistance and to
nhance sensitivity of human cancer cells to chemo- and/or radio-
herapy. Of these, two methods, which we previously reported in
he journals of Oncogene (2011) [14] and Cancer Med. (2013) [15],
re introduced in this article.
. Overcoming chemoresistance in cancer cells
Our recent microarray analysis combined with the ingenuity
athway analysis (IPA) software identiﬁed several genes (LUM;
hosphodiesterase 3B, PDE3B; platelet-derived growth factor-C,
DGF-C; neuregulin 1, NRG1; and polycystic kidney disease 2,
KD2) associated with signiﬁcant increases in CDDP-resistant can-
er cells compared with CDDP-sensitive cancer cells [16]. Of these
enes, we focused on PDE3B, because of the presence of its inhibitor,
ilostazol.
To determine a causal link between CDDP sensitivity and PDE3B
ene expression, messenger RNA (mRNA) expression was  blocked
n transfecting cells with PDE3B short hairpin RNA (shRNA) in Sa3-
 and HeLa-R cells, which are CDDP-resistant cells derived from
ensitive Sa3 and HeLa cells, respectively. Western blot analysis
etermined the PDE3B expression in the knockdown cells and non-
arget control (shNT) cells (Fig. 1a and b). Although there was  no
igniﬁcant difference in cellular proliferation between the shNT and
nockdown cells, knockdown of PDE3B expression with 0.5 g/mL
f PDE3B shRNA led to signiﬁcant (P < 0.05, Mann–Whitney U test)
brogation of CDDP resistance in both CDDP-resistant cells (Fig. 1c)
nd restored the CDDP resistance to the level in the vehicle and
hNT control. These results indicated that PDE3B could play a spe-
iﬁc role in CDDP resistance.
The  main focus of the drug resistance of PDE3B has been
etabolic regulation including insulin sensitivity regulated by
yclic adenosine monophosphate (cAMP) and cyclic guanosine
onophosphate (cGMP) in adipocytes [16–18]. However, consid-
rable evidence has suggested that cAMP and cGMP are crucial
ntracellular second messengers that regulate a wide variety of
ellular processes including proliferation and apoptosis [19,20].
berrant regulation of these messengers might be an impor-
ant mechanism of CDDP resistance [21,22]. Moreover, among theernational 12 (2015) 43–52
known PDE gene families, PDE3B is the most abundantly expressed
form in human leukemia cells [23]. We  also found that cAMP
and cGMP were more active in the PDE3B-knockdown CDDP-
resistant cells than in the parental cells (Fig. 1d). In addition to
cAMP/cGMP inhibition, signiﬁcant downregulation of multidrug
resistance-associated protein-2 (MRP-2) protein expression, medi-
ated by cGMP [24], was  detected in the knockdown cells (Fig. 1b).
Our data and the other observations suggested a potential link
between PDE3B overexpression, which results in MRP-2 upregu-
lation through cAMP/cGMP degradation, and CDDP resistance in a
series of human cancer cells.
Considerable evidence has indicated that a series of chemical
inhibitors stops PDE3B expression [25]. We  used cilostazol, a puta-
tive selective PDE3 inhibitor, in the current study, because it has
been used to treat human diseases [26–29]. Cilostazol increases
the cellular levels of cAMP by inhibiting its degradation [30] and
it inhibits the proliferation of canine Madin–Darby cells [31]. To
further investigate the mechanism by which reduction of PDE3B
alters CDDP resistance, the Sa3-R and HeLa-R cells were exposed
to cilostazol. As in PDE3B-knockdown cells, both CDDP-resistant
cells had enhanced CDDP sensitivity in the presence of cilosta-
zol with elevated cAMP/cGMP activation (Fig. 1e). We found no
such improvement in the parental cells with a low mRNA level
of the PDE3B gene. These data are consistent with the possibility
that cilostazol might be a novel cancer drug that prevents PDE3B
expression in CDDP-resistant cells.
We then determined whether cilostazol affects the tumor
response to CDDP in vivo by evaluating the use of cilostazol to
target tumor xenografts in mice. The Sa3/Sa3-R and HeLa/HeLa-
R cells were inoculated subcutaneously into female athymic nude
mice, and these cells grew to a mean volume of 100 mm3. The
response of each target xenograft to CDDP plus cilostazol was
enhanced signiﬁcantly (P < 0.01, Mann–Whitney U test) only in the
CDDP-resistant cells, compared with controls and systemic ther-
apy with CDDP alone and cilostazol alone. In the parental cells,
systemic cilostazol reduced the mean tumor volume by 32.2%
(1212.3 ± 223.7 mm3 compared with 1785.6 ± 273.9 mm3 in the
control group; n = 5) in Sa3 cells, and 16.1% (1258.4 ± 97.9 mm3
compared with 1499.6 ± 116.2 mm3 in the control group; n = 5) in
HeLa cells (Fig. 2c). CDDP only reduced the mean tumor volume
by 89.0% (197.8 ± 21.2 mm3 compared with 1785.6 ± 273.9 mm3 in
the control group; n = 5) in Sa3 cells and 85.5% (218.8 ± 44.5 mm3
compared with 1499.6 ± 116.2 mm3 in the control group; n = 5)
in HeLa cells (Fig. 2a and c). The effect of systemic cilostazol
combined with CDDP did not differ for each single adminis-
tration. By contrast, the resistant cells had consistently smaller
tumors than control animals with combined treatments; the tumor
volume decreased by about 90.0% (262.2 ± 56.1 mm3 compared
with 2607.2 ± 276.4 mm3 in the control group; n = 5, P < 0.01)
in Sa3-R cells and 84.9% (215.9 ± 41.9 mm3 compared with
1430.0 ± 199.4 mm3 in the control group; n = 5, P < 0.01) in HeLa-R
cells (Fig. 2b and d). Because cellular proliferation and apopto-
sis can regulate tumor size at any given time, we  performed
immunohistochemistry of tumor tissues to measure the prolifer-
ation cell nuclear antigen (PCNA) and Ki67 and cleaved caspase3
expression to measure apoptosis. Decreased proliferation and
enhanced apoptosis were most pronounced in the combined-
treatment group (average PCNA-, Ki67-, and caspase3-positive
staining scores were 209.2 ± 6.4, 124.0 ± 2.9, and 16.2 ± 0.6 for the
control; 132.8 ± 3.9, 105.4 ± 4.6, and 51.6 ± 0.9 for cilostazol alone;
46.0 ± 1.4, 85.2 ± 2.3, and 77.2 ± 2.2 for CDDP alone; and 23.6 ± 1.2,
7.0 ± 0.4, and 117.8 ± 1.4 for combination therapy, respectively;
P < 0.05) for HeLa-R cells (Fig. 3). Our ﬁndings suggested that
the enhanced CDDP sensitivity resulting from a combination of
CDDP and cilostazol are attributable partly to increased apopto-
sis and reduced tumor cell proliferation. The current study did not
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Fig. 1. Analyses of PDE3B inhibition in vitro. (a) Quantiﬁcation of PDE3B mRNA expression in Sa3-R and HeLa-R cells transfected with shPDE3B by qRT-PCR analysis. qRT-PCR
shows that PDE3B mRNA expression in shPDE3B-transfected cells (Sa3-R and HeLa-R derived transfectants) are signiﬁcantly lower than in the shMock-transfected cells
(**P < 0.01, Mann–Whitney U test). (b) Western blot analysis of PDE3B and MRP2 protein in Sa3-R and HeLa-R cells transfected with shPDE3B. Western blot analysis shows
that the PDE3B and MRP2 protein levels in shPDE3B-transfected cells (Sa3-R and HeLa-R derived transfectants) are also decreased markedly compared with that in the
shMock-transfected cells. (c) Effect of CDDP on the clonogenic survival of Sa3-R and HeLa-R cells transfected with shRNAs. The results are expressed as the means ± SEM.
The  signiﬁcance of the difference between shMock and shPDE3B is indicated by asterisks (*P < 0.05, Mann–Whitney U test). (d) The levels of cAMP and cGMP in shPDE3B-
transfected cells (Sa3-R and HeLa-R derived transfectants). Both cAMP and cGMP levels in the PDE3B-knockdown CDDP-resistant cells are signiﬁcantly more active than
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y which reduction of PDE3B alters CDDP resistance, Sa3-R and HeLa-R cells were
resence of cilostazol with elevated cAMP/cGMP activation [15].
rovide direct evidence of a treatment beneﬁt for PDE3B-
xpressing tumors, but cilostazol has been the most commonly
sed and well-tolerated drug for treating peripheral arterial disease
32], indicating its treatment potential.. Enhancement of radiosensitivity in cancer cells
Recently, our microarray analysis combined with the inge-
uity pathway analysis (IPA) identiﬁed six genes (ID1; ID3; PDE3 inhibitor, on cAMP/cGMP activation. To further investigate the mechanism
sed to cilostazol. Both CDDP-resistant cells had enhanced CDDP sensitivity in the
ﬁbroblast  growth factor receptor 3, FGFR3; PEG10; intercellular
adhesion molecule 2, ICAM2; and matrix metallopeptidase 13,
MMP13) associated with signiﬁcant increases in radioresistant cells
compared with radiosensitive cells in a dose-dependent and a
time-dependent manner [32]. Of them, the receptors of FGFR3
gene regulate proliferation, differentiation, migration, and apo-
ptosis [33,34]. To verify whether the FGFR3 gene is associated
with radioresistance in vitro, we performed a small interfering
RNA (siRNA) experiment to inhibit the expression of FGFR3 in the
46 H. Tanzawa et al. / Oral Science International 12 (2015) 43–52
Fig. 2. Analyses of PDE3B inhibition in vivo. Antitumor activity of cilostazol combined with CDDP in the two  sets of cell lines (Sa3 (a)/Sa3-R (b) and HeLa (c)/HeLa-R (d))
xenografts. The cells (2 × 106) were injected subcutaneously into the backs of female athymic nude mice. When the volume of the transplantation tumor reached 100 mm3,
the  mice were assigned randomly into four treatment groups: control, cilostazol alone, CDDP alone, and cilostazol combined with CDDP. The values represent the mean
tumor size ± standard error of the mean (SEM) (n = 5/group). The asterisks indicate signiﬁcant differences from CDDP treatment alone (*P < 0.05, **P < 0.01, respectively,
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tann–Whitney U test). The tumor tissues from the control, cilostazol alone, CDDP
ere  prepared for hematoxylin and eosin staining and immunohistochemistry o
agniﬁcation 400× [15].
SC-2 (radioresistant) cell line, whose expression of FGFR3 was
eported to be higher than in the HSC-3 (radiosensitive) cell line
32]. A series of cell growth experiments was performed to deter-
ine the effect of FGFR3 siRNA on the growth of the cancer cell
ines. The growth curves of the HSC-2 cells showed that although
reatment with FGFR3 siRNA signiﬁcantly (P < 0.01, Student’s t-test)
nhibited cell growth over 6 days, cell growth was not inhibited by
ehicle and nontarget control (siNT) (Fig. 4b). Fig. 4a shows the
estern blot analysis results of FGFR3 protein expression in HSC-
 cells 120 h after transfection with siRNAs. This time point was
hosen by a positive silencing control test in an siRNA transfec-
ion experiment (data not shown). The FGFR3 protein expression, and combination groups were ﬁxed in 10% formalin, and parafﬁn sections (4 m)
iferating cell nuclear antigen (PCNA), Ki67, and cleaved caspase3 assay. Original
level  signiﬁcantly decreased (P < 0.01, Student’s t-test) compared
with nontransfected, vehicle-transfected, and siNT-transfected
cells.
Next, we determined the effect of radiosensitivity in FGFR3-
knockdown HSC-2 cells. Fig. 4c shows the radiation survival
curves of untreated control cells and cells transfected with siR-
NAs. These data were used to calculate the dose of D37 required
to reduce survival to 37% [35]. For the HSC-2 cells, the D37 doses
of the control, vehicle, siNT, and siIFGFR3 were 6.4, 7.4, 6.0,
and 4.3 Gy, respectively. Compared with the vehicle-treated con-
trols, at the 37% survival level, the radiosensitivity of siFGFR3
cells was  enhanced by a dose-modifying factor of 1.72 (D37
H. Tanzawa et al. / Oral Science International 12 (2015) 43–52 47
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ounted (ﬁve random ﬁelds per slide from a total of ﬁve slides per study group; 
ifferences from the controls (*P < 0.05, **P < 0.01, respectively, Mann–Whitney U te
alues of vehicle/D37 values of siFGFR3), and the radiosensitivity
f cells was 1.23-fold (D37 values of vehicle/D37 values of siNT).
As  stimulation of cell proliferation and differentiation by
GF receptors acts via activation of the extracellular signal-
egulated kinase (ERK) pathway [36,37], we assessed the effect of
 small-molecule FGFR inhibitor (PD173074) on ERK phosphory-
ation. Sequential increases in the PD173074 concentration led to
ecreased phosphorylation of ERK at 1, 3, and 6 h after treatment
Fig. 5), indicating that the effect of PD173074 on cells contin-
ed from 1 to 6 h. Therefore, we performed the radiosensitivity
ssay 3 h after the PD173074 treatment. PD173074 (100 nM)  also
nhibited cell growth compared with the control cells (Fig. 6a).
imilar to the results of the siRNA experiment, enhanced radiosen-
itivity was detected in HSC-2 cells treated with PD173074
Fig. 6b). For PD173074-treated HSC-2 cells, the D37 doses of the
ontrol, dimethyl sulfoxide (DMSO), and 5, 25, and 100 nM of
D173074 were 5.68, 5.63, 5.43, 3.63, and 3.89 Gy, respectively.
ompared with the DMSO-treated controls, at the 37% survival
evel, the radiosensitivity of cells treated with 100 nM PD173074ults are expressed as the number of PCNA-, Ki67-, or caspase3-positive cells/ﬁeld
ﬁcation 100×). Data represent the mean ± SEM. The asterisks indicate signiﬁcant
].
was  enhanced by a dose-modifying factor of 1.45 (D37 values of
DMSO-treated controls/D37 values of 100 nM PD173074).
To further analyze the effect of PD173074 on other types of
human cancer cells, we used human lung cancer cells, HARA and
A549. Similar to the HSC-2 cells, PD173074 enhanced the radiosen-
sitivity in both cell lines (Fig. 6c and d).
We then determined whether PD173074 affected the tumor
response to radiotherapy. The HSC-2 cells were inoculated subcu-
taneously into female athymic nude mice and allowed to grow to
a mean volume of 100 mm3. The response of the HSC-2 xenografts
to radiation plus PD173074 was  enhanced signiﬁcantly (P < 0.01,
Student’s t-test) compared with controls and systemic therapy
with radiation alone and PD173074 alone (Fig. 7a). Treatment with
systemic PD173074 reduced the mean tumor volume by 39.9%
(1523.5 ± 257.8 mm3 compared with 2535 ± 437.5 mm3 in the con-
trol group; n = 5) (Fig. 4a). Similarly, treatment with only radiation
reduced the mean tumor volume by 57.9% (1066.2 ± 101.7 mm3
compared with 2535 ± 437.5 mm3 in the control group; n = 5)
(Fig. 7a). Systemic PD173074 combined with radiation resulted in
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Fig. 4. (a) Western blot analysis of FGFR3 protein in HSC-2 cells transfected with siFGFR3. HSC-2 cells were plated at a density of 1 × 105/well in 24-well culture plates.
Cells were transfected 24 h after plating with 100 nM siRNA targeting FGFR3 (OnTarget plus SMARTpool, Dharmacon, Lafayette, CO, USA; cat # L-003133-00) or nontargeting
pool (OnTarget plus nontargeting pool # 1, Dharmacon, cat # D-00181-01) using DharmaFect 1 (Dharmacon) for 3 days before the experiments. Cells were lysed in buffer
(10  mM Tris base (pH 8.0), 400 mM NaCl, 3 mM MgCl2, 0.5% Nonidet P-40 (Sigma, St. Louis, MO,  USA), 100 mM phenylmethylsulfonyl ﬂuoride, and 0.01% protease inhibitor
cocktail (Sigma)) at 4 ◦C for 10 min. Protein extracts were separated by SDS-PAGE in 11% gel, transferred to polyvinylidene ﬂuoride membranes (Bio-Rad, Hercules, CA, USA),
and  blocked for 1 h at room temperature in 0.3% skimmed milk. The membranes were incubated overnight with antibodies against rabbit anti-human FGFR3 polyclonal
antibody (Abcam, Cambridge, UK) and mouse anti-human -actin monoclonal antibody (Abcam) at 4 ◦C. The membranes were washed with 0.1% Tween-20 in TBS (TBS-T)
and  incubated with secondary antibodies, HRP-conjugated anti-rabbit or anti-mouse IgG (Promega, Madison, WI,  USA), for 1 h at room temperature. Finally, the membranes
were incubated with the ECL+ kit (GE Healthcare, Buckinghamshire, UK), and immunoblotting was visualized by exposing the membrane to Hyperﬁlm (GE Healthcare). (b)
To  investigate the effect of FGFR3 siRNA on cell proliferation, siFGFR3- and nontargeting siRNA-transfected HSC-2 cells, and vehicle cells were seeded in 12-well plates at
a  density of 1 × 104 viable cells/well. The vehicle control cells were treated with only DharmaFECT1 reagent. At the indicated time points, the cells were trypsinized and
counted using a hemocytometer in triplicate samples. The results represent the mean ± SD. The asterisks indicate signiﬁcant differences between siNT and siFGFR3 (*P < 0.05,
**P < 0.01, Student’s t-test). (c) The effect of radiation on the clonogenic survival of HSC-2 cells transfected with siRNAs. At 96 h after transfection, the cells were trypsinized
and plated in 60-mm dishes for clonogenic survival assay for siFGFR3. After 24 h, when the cells had attached, they were irradiated with four single-radiation doses (2, 4,
6,  and 8 Gy) using X-ray irradiation equipment (MBR-1520R-3; Hitachi, Tokyo, Japan) operated at 150 V and 20 mA with aluminum ﬁltration, at a dose of 2.1 Gy/min. The
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onsistently smaller tumors than in control animals, with the tumor
olume being reduced by about 90% (242.2 ± 116.6 mm3 compared
ith 2535 ± 437.5 mm3 in the control group; n = 5, P < 0.01) (Fig. 7a).
Although considerable evidence has suggested that mutations
n the FGFR3 gene are associated with severe skeletal dyspla-
ia [38], abnormalities of this gene leading to its overexpression
ave also been identiﬁed in a variety of human cancers, includ-
ng multiple myeloma and glioblastoma, and bladder, prostate,
ervix, and breast cancers [38–41]. These ﬁndings strongly sug-
ested the oncogenic properties of the FGFR3 mutated receptor.
GFR3, an elevated mRNA expression level of which was detected
n radioresistant human SCC cell lines in our previous study [32],
as found to be a candidate for radioresistant enhancements in SCC
ells using microarray analysis. A more recent study also reported relationship between FGFR3 and radiation sensitivity in artiﬁ-
ially FGFR3-reduced oral SCC cells [42]. To date, no studies have
een published on the functional signiﬁcance of radiation sensitiv-
ty by inhibition of FGFR3 expression. Thus, the current study was. Clonogenic fractions of irradiated cells were normalized to the plating efﬁciency
ars represent ± SD. The signiﬁcance of the difference between siNT (triangles) and
designed  to further examine whether FGFR3 is functionally asso-
ciated with the radiosensitivity of human SCC cells in vitro and in
vivo.
Downregulation of FGFR3 in HSC-2 cells induced signiﬁcant
radiosensitivity in vitro, which indicated the important role of
FGFR3 in radioresistant SCC cells. Another important point is that
radiosensitization of cells may  depend on the degree of FGFR3 pro-
tein inhibition. Because HSC-2 cells were incubated for a longer
time with siFGFR3, they became more radiosensitive (Fig. 4c), sug-
gesting that radiosensitization of HSC-2 cells may  be determined by
the amount of FGFR3 protein in the cells at the time of irradiation.
PD173074, the pharmacologic FGFR inhibitor, is a synthetic
compound of the pyrido(2,3-d)pyrimidine class that inhibits tyro-
sine kinase activities and inhibits several FGFR families including
FGFR3 in human cancer cells [43,44]. In addition, because FGFR3
signals partly through the Ras/MAP kinase pathway [45], we
assessed the effect of the inhibitors on ERK phosphorylation. In
response to treatment with PD173074, the radioresistant cell line
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Fig. 5. Dose-dependent decreases in ERK phosphorylation in HSC-2 cells by
PD173074.  The antibodies against mouse anti-human ERK1/2 monoclonal antibody
(Santa Cruz Biotechnology, Santa Cruz, CA, USA) and mouse anti-human p-ERK1/2
monoclonal  antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) were used
for Western blotting. The membranes were washed with TBS-T and incubated with
secondary antibodies, HRP-conjugated anti-rabbit or anti-mouse IgG (Promega), for
1 h at room temperature [14].
Fig. 6. (a) To determine the effect of FGFR inhibitor on cell proliferation, HSC-2 cells we
density of 1 × 104 viable cells per well, and they were treated with PD173074 (5, 25, an
points, the cells were trypsinized and counted using a hemocytometer in triplicate sample
between 0 nM/DMSO and 100 nM (*P < 0.05, **P < 0.01, Student’s t-test). (b–d) The effect
appropriate number of cells was plated in 60-mm dishes and allowed to attach for 24 
treatment, the cells were irradiated (2, 4, 6, and 8 Gy) and incubated for 8–10 days. The
counted. Clonogenic fractions of irradiated cells were normalized to the plating efﬁcienc
error  bars represent ± SD. The asterisks indicate signiﬁcant differences between 0 nM/DMernational 12 (2015) 43–52 49
(HSC-2) underwent radiosensitization with decreased phosphory-
lation of ERK (Fig. 5). It is also worth noting that the previously
mentioned chemical effect was  observed in a different set of lung
cancer cell lines. These results suggested that FGFR3 may regu-
late radioresistance in human cancer cells by activation of the
Ras/mitogen-activated protein (MAP) kinase pathway, resulting in
upregulation of a number of critical genes.
Most importantly, our in vitro results were reproduced in
vivo. Although the antitumor effects were limited with the
doses of radiation administered and PD173074 administered
alone, tumor growth was  inhibited markedly when the treat-
ments were combined (Fig. 7a). Cell proliferation and apoptosis
can regulate the tumor size at any given time. Therefore, we
performed immunohistochemistry in tumor tissues to measure
the proliferation cell nuclear antigen (PCNA) expression and
the terminal deoxynucleotidyl transferase-mediated deoxyuridine
triphosphate (dUTP)-biotin nick end labeling (TUNEL) assay to
measure apoptosis. As shown in Fig. 4a and b, decreased pro-
liferation (PCNA) and enhanced apoptosis (TUNEL) were most
pronounced in the combination-treated group (average PCNA- and
TUNEL-positive staining cells were 47.2 ± 3.0 and 7.6 ± 2.3 for con-
trol, 30.6 ± 5.2 and 17.3 ± 4.3 for PD173074 alone, 27.6 ± 4.5 and
18.8 ± 5.9 for radiation alone, and 6.8 ± 3.3 and 33.2 ± 5.9 for com-
bination, respectively; P < 0.05). Thus, our ﬁndings suggest that
re treated with PD173074. Brieﬂy, HSC-2 cells were seeded in 12-well plates at a
d 100 nM). The control cells were treated with only DMSO. At the indicated time
s. The results represent the mean ± SD. The asterisks indicate signiﬁcant differences
 of PD173074 on radiosensitivity in HSC-2 (b), HARA (c), and A549 (d) cells. The
h. The cells were treated with PD173074 (0, 5, 25, and 100 nM)  for 3 h. After the
 colonies were stained with crystal violet (Sigma), and colonies of ≥50 cells were
y of unirradiated controls. Each experiment was repeated at least three times; the
SO and 100 nM (*P < 0.05, **P < 0.01, Student’s t-test) [14].
50 H. Tanzawa et al. / Oral Science International 12 (2015) 43–52
Fig. 7. (a) Antitumor activity of PD173074 combined with radiation in HSC-2 cell line xenografts. The HSC-2 cells were injected subcutaneously into the lower limb of female
athymic nude mice, BALB/cAnNcrj-nu/nu purchased from Charles River Japan Inc. (Yokohama, Kanagawa, Japan). The care and treatment of experimental animals were in
accordance  with institutional guidelines. Mice were injected in the lower limb subcutaneously with 2 × 107 HSC-2 (radioresistant) cells. When the volume of transplantation
tumor reached 100 mm3, 10 mice/group were treated with PD173074 (25 mg/kg intraperitoneally on days 0–4 each week for 2 weeks) and/or radiation (4 Gy on days 0–4
each  week for 2 weeks). The animal experiments included four treatment groups: control (n = 5), PD173074 alone (n = 5), radiation alone (n = 5), and radiation combined with
PD173074 (n = 5). Caliper measurements of the longest perpendicular tumor diameters were performed on alternate days to estimate the tumor volume, using the following
formula: 4/3 × (width/2)2 × (length/2). After the volume of transplantation tumor reached 100 mm3, the mice were treated with PD173074 (25 mg/kg intraperitoneally
on days 0–4 each week for 2 weeks) and/or radiation (4 Gy on days 0–4 each week for 2 weeks). The values represent the mean tumor size ± SEM (n = 5/group). **P < 0.01,
Student’s t-test, compared with the respective control. Effects of PD173074 combined with radiation on tumor cell proliferation and apoptosis. The tumor tissues, derived
from  four groups (control, PD173074 alone, radiation alone, and radiation combined with PD173074) were ﬁxed in 10% formalin and parafﬁn sections (4 m)  prepared for
hematoxylin and eosin (H&E) staining, immunohistochemistry of PCNA, and the TUNEL assay. For PCNA, tissue sections were stained with primary antibody against PCNA
(Abcam). Brieﬂy, after deparafﬁnization and hydration, the endogenous peroxidase activity was quenched by 30-min incubation in a mixture of 0.3% hydrogen peroxide
solution in 100% methanol, after which the sections were blocked for 2 h at room temperature with 1.5% blocking serum (Santa Cruz Biotechnology) in PBS before reaction
with anti-PCNA antibody (1:100 dilution) at 37 ◦C in a moist chamber overnight. Upon incubation with the primary antibody, the specimens were washed three times in
PBS  and treated with Envision reagent (DAKO, Carpinteria, CA) followed by color development in 3,3′-diaminobenzidine tetrahydrochloride (DAB, DAKO). The slides then
were  dehydrated with ethanol, cleaned with xylene, and mounted. Nonspeciﬁc binding of an antibody to proteins other than the antigen sometimes occurred. As a negative
control, triplicate sections were immunostained without exposure to primary antibodies, which conﬁrmed the staining speciﬁcity. TUNEL staining was  performed using an
ApopTag  Peroxidase in situ Apoptosis Detection Kit (S7100, Chemicon, Billerica, MA, USA) and visualized using DAB, according to the manufacturer’s instructions. Original
magniﬁcation 400×. (b) Quantiﬁcation of PCNA- and TUNEL-positive cells. Tumor slides of different groups were visualized under the microscope, and PCNA- and TUNEL-
positive cells were quantiﬁed. Results were expressed as the number of PCNA- or TUNEL-positive cells/ﬁeld counted (5 random ﬁelds per slide from a total of 5 slides per
study  group, magniﬁcation 100×). Data represent mean ± SEM. The asterisks indicate signiﬁcant different from respective controls (*P < 0.05, Student’s t-test). (c) Athymic
nude mice without injection of oral cancer cells were randomly placed into either a vehicle control group (DMSO) or a group treated with PD173074. Body weight was
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reasured throughout the 35 days of treatment (upper panel). Values shown repres
anel)  treated with radiation only and radiation plus PD173074 were assessed usin
epresent the mean skin reaction score ± SEM (n = 5/group) [14].
he enhanced radiosensitizing effects, observed when PD173074
s combined with radiation, are attributable in part to not only
ncreased apoptosis but also reduced tumor cell proliferation.
We  have found that the average body weight of the mice in
he PD173074 treatment group never became lower than that of
he control group (radiation only) at any point of the experiment
Fig. 7c). No signiﬁcant difference in skin reaction during irradiation
reatment was also detected between the radiation-only group and
adiation plus PD173074 group (Fig. 7c). In addition to our results,e mean ± SEM (n = 5/group). Acute skin reactions on the lower limb of mice (lower
rbitrary [46]. The scoring system comprised eight degrees, from 0 to 3.5. The values
a  recent study has reported that oral PD173074 is available and no
toxicity was  observed in treated mice [47]. Therefore, these results
further support our hypothesis that FGFR3 is an important target in
overcoming de novo and acquired radioresistance in human SCCs.
Taken together, these data suggested that FGFR inhibition could
provide a powerful radiotherapeutic strategy for treating SCC in
clinical settings. The therapeutic potential of PD173074 in the radi-
ation treatment of SCC has led to the development of promising
strategies to deliver PD173074 in vivo.
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. A perspective
Although the mechanism of CDDP resistance has been reported
o be associated with multiple factors [48], to our knowledge, our
revious reports were the ﬁrst on the combined use of CDDP and
 PDE3B inhibitor, cilostazol, and on the combination of radiation
nd an FGFR3 inhibitor, PD173074, in vitro and in vivo [14,15]. The
urrent data supported the idea that these combination therapies
ncrease the therapeutic efﬁcacy of chemo- and/or radiotherapy in
uman cancers, and they could conceptually or strategically affect
he design of future clinical trials for patients with cancer.
Numerous drugs that enhance CDDP sensitivity should be devel-
ped. However, detecting a clinically useful drug such as cilostazol
nd PD173074 is very difﬁcult. Many researchers have detected
any candidate genes. When the candidate gene was inhibited by
enetic methods such as siRNA, the therapeutic efﬁcacy in human
ancers is increased. However, few drugs that inhibit or stimulate
he candidate gene have been found. We,  as researchers, should
onsider new methods.
Drug  repositioning is the application of known drugs and com-
ounds to new indications [49]. In the current study, we re-proﬁled
ne drug, cilostazol, and one compound, PD173074, and found their
ew clinical indications. Cilostazol is clinically known and used as
n antiplatelet drug for peripheral vascular disease. PD173074 was
 compound that was not applied to clinical use although it was
nce developed as an anticancer drug. A signiﬁcant advantage of
rug repositioning over traditional drug development is that the
epositioned drug has already passed a signiﬁcant number of tox-
city and other tests, avoiding failure during development and the
igh costs.
Currently, it is a very exciting period in research because many
ew targets have been detected. Researchers should consider the
ew roles of drugs in cancer therapy.
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